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Angioscopic Comparison
of Neointimal Coverage
Between Zotarolimus-
and Sirolimus-Eluting Stents
Drug-eluting stents (DES) have demonstrated reduced late loss
(LL) and low target lesion revascularization (TLR) rates through
an inhibitory effect on neointimal hyperplasia but might have a risk
of late or very late stent thrombosis due to incomplete neointimal
coverage (NIC) (1–3). A zotarolimus-eluting stent (ZES) (En-
deavor, Medtronic, Minneapolis, Minnesota) is a next-generation
DES that shows higher LL than a sirolimus-eluting stent (SES)
(Cypher, Cordis, Miami, Florida), while demonstrating favorable
inhibitory effects on TLR. We hypothesize the differences in LL
will be reflected in different healing processes and might in part
explain observed differences in safety. With angioscopy, we inves-
tigated the lumen/stent surfaces after placement of ZES for de
novo lesions of the native coronary arteries and compared the
findings with SES.
We investigated 30 DES implanted in 28 patients (21 men, age
range from 43 to 83 years old) who suffered from stable angina
pectoris, fulfilled the matching criteria, and agreed to receive
follow-up angioscopy as well as angiography. Eighteen ZES were
implanted in 18 consecutive patients who fulfilled the matching
criteria. Follow-up angiography was performed approximately 8
months after stent implantation in all patients, and 14 of these
patients (14 stents) agreed to receive follow-up angioscopy. These
angioscopic findings were compared with the pooled data of 16
SES in 14 consecutive patients who also fulfilled the matching
criteria. These patients all agreed to receive follow-up angioscopy
8 months after implantation. Matching criteria included: 1) de
novo lesion of 50% diameter stenosis, which caused myocardial
ischemia; 2) native coronary artery of 2.25 to 3.5 mm diameter; 3)
nonacute coronary syndrome culprit lesions; and 4) total stented
length 47 mm. All patients were taking aspirin 100 to 200
mg/day. Ticlopidine 200 mg/day was additionally given for at least
3 months. Neither glycoprotein IIb/IIIa inhibitors nor clopidogrel
was used, because they were not approved for clinical use in Japan
at the time of this study. The medical ethics committee at Kansai
Rosai Hospital approved the study, and all patients gave written
informed consent.
The NIC was angioscopically classified into 4 grades (Fig. 1) as
previously described (1,2). In brief, grade 0: stent struts were
exposed; grade 1: struts bulged into the lumen, although they were
covered; grade 2: struts were embedded but were seen translu-
cently; and grade 3: struts were fully embedded and invisible. If
NIC was heterogeneous, the dominant pattern was adopted. All
results are expressed as mean  SD unless otherwise stated.
Comparisons between the 2 groups were done with the Wilcoxon
rank sum test. Categorical variables were analyzed with the Fisher
exact test for 2 2 comparisons; for more than 2 2 comparisons,
the chi-square test was used. Statistical significance was defined as
p  0.05.
Patient, lesion, and procedure characteristics were equally dis-
tributed between ZES and SES. Implanted stent diameter was
3.22  0.31 mm in SES versus 3.04  0.41 mm in ZES (p 
0.22); stent length was 22.7 3.40 mm in SES versus 21.9 4.47
mm in ZES (p 0.97). Although SES had a trend toward smaller
reference diameters than ZES (2.89 0.40 mm in SES vs. 3.22
0.74 mm in ZES, p  0.23), baseline angiogram showed no
statistical differences. Although the minimal lumen diameter after
procedure also tended to be smaller in SES (2.70  0.34 mm in
SES vs. 3.02  0.51 mm in ZES, p  0.08), in-stent LL from
post-procedure to follow-up was smaller in SES (0.07  0.18 mm
in SES vs. 0.51  0.17 mm in ZES, p  0.0001), reaching the
similar minimal lumen diameter and percent diameter stenosis at
follow-up. None of the lesions showed restenosis.
The ZES showed greater NIC grades than SES (p  0.0004,
chi-square test) (Figs. 1 and 2). Thrombi tended to be more
frequent in SES (31%) than in ZES (7%, p  0.2, Fisher exact
test). All thrombi were mural, subclinical, and associated with sites
with grade 0 or 1. A red thrombus was detected in a ZES at a grade
1 site, although the dominant grade was grade 2. Yellow plaques
(YP) were detected in 2 ZES versus in 11 SES (p  0.004, Fisher
exact test), which were all detected underneath the neointima at
sites showing grades 0 to 2 coverage.
This study is the first to compare the 2 different platforms of
DES with angioscopy. In contrast to SES, ZES had NIC similar
to what we had seen previously in bare-metal stents (BMS) (2).
The frequency of mural thrombus tended to be lower and YP were
less frequently visible in ZES than in SES.
A DES platform with extremely limited LL and low restenosis
rates might have a risk of incomplete NIC and subsequent late or
very late stent thrombosis. Whereas ZES showed a greater in-stent
LL than SES, the majority of ZES showed complete NIC similar
to BMS (2). Angioscopic grade 0/1 coverage might be a conse-
quence of delayed endothelialization. An animal study demon-
strated that the extent of stent coverage by endothelial cells was
greater with ZES, with almost complete coverage, than with SES
Figure 1 Angioscopic Classification ofNeointimal Coverage at Follow-Up in 30 Stents
Seventy-one percent of zotarolimus-eluting stents (ZES) showed grade 3 neoin-
timal coverage, whereas 6% of sirolimus-eluting stents (SES) showed grade 3
coverage. Neither grade 0 nor grade 1 was detected in ZES. The shadowed
portion indicates the incidence of thrombus adhesion. ZES versus SES: p 
0.0004.
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at 21 days after the placement in the rabbit iliac arteries (4). All
thrombi observed in this study were found at grade 0/1 sites; the
dominant pattern in ZES-implanted vessels in this study was grade
2/3 with less adhesion of thrombus. The ZES-implanted vessels
were associated with significantly less yellow plaques than SES.
Yellow plaque is also reduced by BMS placement, because both the
stent and the YP underneath the stent are covered by neointimal
development (5). The ZES is likely to have a “sealing” effect,
because ZES shows NIC more like that of BMS. These angio-
scopic findings suggest that arterial endothelial healing of ZES at
8 months after stent placement was more competent than SES. In
general, mean in-stent LL below 0.65 mm with stent platforms is
associated with TLR rates below 10% (6). Considering the risk
of stent thrombosis due to incomplete NIC, it is preferable for
DES to have sufficient neointimal volume no greater than LL of
0.65 mm.
Although the single-center, nonrandomized, matched-control,
and observational nature with a small sample size of this study
should be noted as a limitation, this study suggests that arterial
endothelial healing after stenting is more competent in ZES than
in SES. Optimal LL might be desirable for adequate arterial
endothelial healing after stenting.
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Letters to the Editor
Adjusting Clopidogrel Loading
Doses According to Vasodilator-
Stimulated Phosphoprotein Index:
On Time, Too Early, or Too Late?
We have read with great interest the report from Bonello et al. (1).
The authors have to be congratulated on publishing the first article
to show the clinical benefit of tailored antiplatelet therapy. We
would like to address a few comments to the authors.
The clinical evidence supporting the clinical predictive value of
the vasodilator-stimulated phosphoprotein (VASP) index is quite
low (2,3), and additional large-sample size studies may be required
to validate a definite cutoff. The authors used a cutoff of 50%,
previously associated with post-percutaneous coronary interven-
Figure 2 Coronary Angioscopic Images8 Months After SES and ZES Implantation
Left images (A, B) show a sirolimus-eluting stent (SES) (3.5  23 mm)
implanted case, and right images (C, D) show a zirolimus-eluting stent (ZES)
(3.5  23 mm) implanted case, both at the proximal portion of the right coro-
nary artery. (A, C) Angiograms at follow-up revealed no restenosis. (B) Angio-
scopic images of SES indicated grade 1 neointimal coverage throughout the
stent, with mural red thrombus adhesion observed at the proximal site of the
stent. Further, yellow plaques were observed underneath the stent (the entire
segment of the stent placed in the vascular wall was yellow). (D) In contrast,
ZES showed grade 3 neointimal coverage throughout the stent. Yellow plaques
existed in the distal native coronary artery adjacent to the distal end of the
stent. The vascular wall showed mild yellow saturation, while the stent portion
was covered with white-gray neointima with no yellow plaques observed (D,
bottom image). Open arrow  mural red thrombus; solid arrows  boundary
line of the neointimal coverage; GW  guidewire.
790 Correspondence JACC Vol. 52, No. 9, 2008
August 26, 2008:787–92
